Zhitong Finance App News, Baiyunshan (00874.HK) issued an announcement. Recently, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as “Tianxin Pharmaceutical”), a holding subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received the “Drug Registration Certificate” for irbesartan hydrochlorothiazide tablets approved and issued by the State Drug Administration.

Zhitong Finance App News, Baiyunshan (00874.HK) issued an announcement. Recently, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as “Tianxin Pharmaceutical”), a holding subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received the “Drug Registration Certificate” for irbesartan hydrochlorothiazide tablets approved and issued by the State Drug Administration.